BCRX

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing novel small-molecule drugs to treat rare diseases. Headquartered in Durham, North Carolina, BioCryst employs structure-guided drug design, a technology-enabled approach that uses detailed knowledge of protein structure and function to precisely design inhibitor molecules. This rational design methodology has enabled BioCryst to develop multiple approved drugs and maintain a pipeline of development-stage candidates addressing significant unmet medical needs. The company's lead commercial product is ORLADEYO (berotralstat), an oral prophylactic treatment for hereditary angioedema (HAE), a rare genetic disorder causing painful and potentially life-threatening swelling attacks. ORLADEYO is the only approved oral preventive HAE medication and represents a significant advancement for patients who previously had limited oral treatment options. BioCryst's pipeline includes galidesivir, a broad-spectrum antiviral in development for multiple viral diseases, and other programs targeting complement-mediated diseases and other rare conditions. BioCryst's structure-based drug design expertise has resulted in multiple approved therapies across its history. The company maintains strategic collaborations and partnerships with pharmaceutical companies and government organizations, including projects funded by government agencies for antiviral development. BioCryst has established commercial operations to support ORLADEYO's global launch and is expanding into new geographies and indications. The company focuses on rare disease markets where innovative therapies can address high unmet needs and provide significant value to patients, families, and healthcare systems. BioCryst's deep expertise in drug design, rare disease development, and commercialization positions it as a leader in its therapeutic areas.